TABLE 5.
Hemagglutination-inhibitory activity against Pan/99 virus of sera from guinea pigs immunized with Pan/99-based live attenuated vaccine
Treatment and guinea pig | Vaccine | Route of challengec | Titer
|
||
---|---|---|---|---|---|
Preimmune | Postvaccinationd | Postchallengee | |||
Live attenuated vaccine, homologous challengea | |||||
47 | PBS | Inoculation i.n. | 10 | 10 | 320 |
48 | PBS | Inoculation i.n. | 10 | 10 | 320 |
49 | PBS | Exposure | 10 | 10 | 320 |
50 | PBS | Exposure | 10 | 10 | 160 |
51 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | 10 | 320 | 160 |
52 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | 10 | 320 | 320 |
53 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | 10 | 320 | 320 |
54 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | 10 | 160 | 160 |
55 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 320 | 320 |
56 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 320 | 320 |
57 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 160 | 160 |
58 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 160 | 160 |
Live attenuated vaccine, heterologous challengeb | |||||
59 | PBS | Inoculation i.n. | 10 | 10 | 20 |
60 | PBS | Inoculation i.n. | 10 | 10 | 20 |
61 | PBS | Exposure | 10 | 10 | 10 |
62 | PBS | Exposure | 10 | 10 | 80 |
63 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | 10 | 1,280 | 1,280 |
64 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | 10 | 1,280 | 2,560 |
65 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | <10 | 640 | 640 |
66 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | 10 | 2,560 | 2,560 |
67 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 1,280 | 5,120 |
68 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 5,120 | 2,560 |
69 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 1,280 | 2,560 |
70 | Pan/99 HA NA:PR8 NS1-73 | Exposure | 10 | 1,280 | 2,560 |